Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Celgene and Juno Therapeutics announce immunotherapy alliance

Celgene and Juno Therapeutics announce immunotherapy alliance

1st July 2015

Celgene is allying with Juno Therapeutics on a ten-year collaboration focusing on the development and commercialisation of new immunotherapies.

The work will see the companies working to leverage T-cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases, with an initial focus on chimeric antigen receptor technology and T-cell receptor technologies.

Celgene will receive an option to commercialise Juno programmes outside North America and co-promote certain programs globally, while Juno gains the option to co-develop and co-promote selected Celgene programmes.

The terms of the deal will see Celgene make an initial payment of approximately $1 billion (638.68 million pounds), which includes the purchase of around 9.1 million shares of Juno stock, with the potential to increase its stake over time.

Bob Hugin, chairman and chief executive officer of Celgene, said: "We believe this long-term collaboration enhances the potential of both companies to deliver transformational therapies to patients with significant unmet medical needs."

This comes after the firm agreed a deal earlier this year to acquire Quanticel Pharmaceuticals, a privately-held biotechnology company focused on cancer drug discovery.ADNFCR-8000103-ID-801793035-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.